1. Home
  2. PUBM vs OMER Comparison

PUBM vs OMER Comparison

Compare PUBM & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PubMatic Inc.

PUBM

PubMatic Inc.

HOLD

Current Price

$16.39

Market Cap

747.5M

Sector

Technology

ML Signal

HOLD

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$18.93

Market Cap

844.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PUBM
OMER
Founded
2006
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
747.5M
844.6M
IPO Year
2020
2008

Fundamental Metrics

Financial Performance
Metric
PUBM
OMER
Price
$16.39
$18.93
Analyst Decision
Buy
Strong Buy
Analyst Count
7
5
Target Price
$12.43
$32.50
AVG Volume (30 Days)
804.1K
2.2M
Earning Date
05-07-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
98.15
EPS
N/A
0.77
Revenue
$282,926,000.00
$29,868,000.00
Revenue This Year
$3.44
N/A
Revenue Next Year
$7.86
$233.22
P/E Ratio
N/A
$24.40
Revenue Growth
N/A
N/A
52 Week Low
$6.15
$3.94
52 Week High
$18.44
$19.65

Technical Indicators

Market Signals
Indicator
PUBM
OMER
Relative Strength Index (RSI) 56.30 69.48
Support Level $8.67 $9.12
Resistance Level $18.44 $19.65
Average True Range (ATR) 0.59 0.97
MACD -0.18 -0.06
Stochastic Oscillator 30.23 70.42

Price Performance

Historical Comparison
PUBM
OMER

About PUBM PubMatic Inc.

PubMatic Inc is is an independent, artificial intelligence-powered advertising technology company that delivers digital advertising performance. Its integrated technology platform connects buyers, publishers, data providers, and commerce media networks on a single, unified platform, to deliver advertising performance, control, transparency and efficiency. Its platform empowers the world's digital content creators (publishers) to maximize monetization of their advertising inventory and audiences and provides control and transparency to buyers, which includes advertisers, agencies, agency trading desks, and demand side platforms (DSPs) (referred as buyers). Geographically, the company generates the majority of its revenue from the United States, followed by EMEA, APAC, and Rest of the World.

About OMER Omeros Corporation

Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.

Share on Social Networks: